Analyst Price Target is $11.00
▲ +195.70% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Evaxion Biotech A/S in the last 3 months. The average price target is $11.00, with a high forecast of $14.00 and a low forecast of $8.00. The average price target represents a 195.70% upside from the last price of $3.72.
Current Consensus is
Buy
The current consensus among 2 polled investment analysts is to buy stock in Evaxion Biotech A/S. This Buy consensus rating has held steady for over two years.
Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase 1/2a trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy that is in pre-clinical stage for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.
Read More